zongertinib + trastuzumab emtansine

**Zongertinib + trastuzumab emtansine** is an investigational combination therapy evaluated for advanced HER2-positive cancers, primarily metastatic breast cancer and metastatic gastric/gastroesophageal junction/esophageal adenocarcinoma. Zongertinib (BI 1810631) is a novel, oral, HER2-selective tyrosine kinase inhibitor that spares EGFR, directly targeting the HER2 protein to block cancer cell growth. Trastuzumab emtansine (T-DM1, Kadcyla) is an antibody-drug conjugate: it combines trastuzumab (a monoclonal antibody targeting HER2) with a cytotoxic agent (DM1) delivered into HER2-expressing tumor cells. The combination seeks to leverage complementary mechanisms—HER2 signaling blockade alongside targeted cytotoxic delivery—to enhance anti-tumor effects in patients who have failed prior HER2-based therapies[1][2][3][4].

Other names

T-DM1T-DM-1T-DM 1zongertinib + T-DM1